Inhibiting USP16 rescues stem cell aging and memory in an Alzheimer's model

Area of Science:

• Neuroscience
• Genetics
• Cell Biology

Background:

• Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia.
• Current AD therapies targeting late-stage pathology have limited efficacy.
• Identifying earlier, targetable phenotypes is crucial for effective intervention.

Purpose of the Study:

• To identify the earliest cellular defect in Alzheimer's disease pathogenesis.
• To investigate USP16 as a potential therapeutic target for early AD intervention.

Main Methods:

• Utilized a mouse model of AD and human fetal cells with mutant amyloid precursor protein.
• Investigated the role of USP16, a histone modifier and antagonist of Polycomb Repressor Complex 1.
• Assessed the impact of USP16 reduction on neural precursor cell (NPC) self-renewal, cognitive function, and downstream signaling pathways.

Main Results:

• NPC dysfunction was identified as the earliest defect in AD, preceding inflammation and plaque formation.
• Genetic reduction of USP16 reversed impaired NPC self-renewal and prevented cognitive deficits in vivo.
• USP16 downregulation decreased expression of the senescence gene Cdkn2a and mitigated aberrant Bone Morphogenetic Signaling (BMP) pathway regulation.

Conclusions:

• USP16 is a novel therapeutic target for early Alzheimer's disease intervention.
• Modulating USP16 can ameliorate NPC defects and rescue memory and learning.
• USP16's novel role in regulating Cdkn2a and BMP signaling offers new avenues for AD treatment.